DIOVAN
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
DIOVAN by Novartis is angiotensin-converting enzyme (ace, kininase ii). Approved for hypertension, to lower blood pressure in adults, older and 2 more indications. First approved in 1996.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIOVAN (valsartan) is an oral angiotensin II receptor blocker (ARB) approved in 1996 for hypertension and heart failure. It selectively blocks AT1 receptors to reduce vasoconstriction and aldosterone secretion, independent of ACE inhibition pathways. The drug treats adults across age ranges and is indicated for hypertension management and reduction of cardiovascular mortality in heart failure patients (NYHA class II-IV).
$24MPart D
LOE ApproachingDeclining
Product is entering loss-of-exclusivity phase with declining Part D spending, signaling shift toward legacy management and potential team restructuring or redeployment.
Mechanism of Action
angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Diovan (valsartan)…
Indications (4)
Worked on DIOVAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.